Does Horizon Blue Cross Blue Shield of New Jersey Cover Viagra?

How Horizon BCBS NJ Generally Handles Viagra and Sildenafil Coverage

Most Horizon BCBS NJ commercial plans place generic sildenafil on a preferred generic tier, meaning members pay a relatively low copay, often $10 to $30 per fill. Brand-name Viagra sits on a non-preferred or specialty tier on the majority of plans, and many employer-sponsored plans explicitly exclude it via a "lifestyle drug" exclusion clause. The difference in out-of-pocket cost between brand and generic can exceed $300 per month.

Why Brand Viagra Is Often Excluded

The FDA approved generic sildenafil in December 2017, and payers moved quickly to shift members toward the lower-cost alternative. FDA records confirm sildenafil's patent expiration and the approval of multiple generic manufacturers. Because therapeutic equivalence between brand and generic is established, most commercial insurers classify brand Viagra as "not medically necessary" when a generic equivalent exists. Horizon BCBS NJ follows this standard payer practice.

What "Lifestyle Drug" Exclusions Mean for Members

New Jersey's state insurance regulations permit commercial plans to exclude drugs deemed purely elective or lifestyle-related. ED medications sometimes fall under this exclusion language, though the exclusion is narrower than many members assume. ED caused by diabetes, prostatectomy, spinal cord injury, or cardiovascular disease is typically classified as a medical condition requiring treatment, not a lifestyle preference. The American Urological Association's 2018 ED guideline distinguishes psychogenic ED from organic ED, and payers often follow that distinction when applying exclusions.

Formulary Tiers Explained

Horizon BCBS NJ uses a multi-tier formulary structure:

| Tier | Drug Type | Typical Copay Range | |---|---|---| | Tier 1 | Preferred generics | $5 to $15 | | Tier 2 | Non-preferred generics | $15 to $40 | | Tier 3 | Preferred brand | $40 to $80 | | Tier 4 | Non-preferred brand | $80 to $150+ | | Tier 5 | Specialty | 20-33% coinsurance |

Generic sildenafil most often lands at Tier 1 or Tier 2. Brand Viagra typically appears at Tier 4 or not at all. Always verify your specific plan's formulary at Horizon BCBS NJ's online drug lookup tool.

The Clinical Case for Coverage: Erectile Dysfunction as a Medical Condition

ED affects approximately 30 million men in the United States, according to NIH epidemiological data. The condition is strongly associated with cardiovascular risk. A landmark analysis published in the Journal of the American College of Cardiology found that ED predicted incident cardiovascular events with a hazard ratio of 1.44 (95% CI 1.27-1.63, P<0.001) independent of traditional risk factors. PDE5 inhibitors like sildenafil have a documented evidence base for organic ED, including a key 1996 Goldstein et al. RCT published in the New England Journal of Medicine (N=532) showing statistically significant improvement in erectile function scores versus placebo (P<0.001).

Sildenafil's Mechanism and Why It Requires a Prescription

Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP in smooth muscle and allowing penile arterial dilation. The FDA's prescribing information for sildenafil requires a prescription because the drug carries real contraindications, including concurrent nitrate use, severe hepatic impairment, and certain inherited retinal disorders. This prescription requirement is itself a reason insurers routinely demand a documented diagnosis before approving coverage.

Cardiovascular Comorbidities Strengthen the Coverage Argument

Men with type 2 diabetes experience ED at rates two to three times higher than the general population, according to research indexed on PubMed. Men who have undergone radical prostatectomy for prostate cancer have ED prevalence estimates ranging from 25% to 75% depending on nerve-sparing technique, per NIH clinical literature. In both populations, the therapeutic intent of sildenafil is clearly medical, not cosmetic, and coverage denials in these groups are frequently overturned on appeal.

What the Evidence Says About Sildenafil Efficacy

The original Goldstein et al. Trial (N=532) showed that sildenafil 100 mg improved the International Index of Erectile Function (IIEF) erectile function domain score by a mean of 7.0 points above placebo [1]. A 2016 Cochrane systematic review of PDE5 inhibitors (51 RCTs, N=8,112) confirmed statistically significant improvements in IIEF scores across all approved doses, with sildenafil showing a standardized mean difference of 0.87 (95% CI 0.73-1.00) versus placebo [2]. These effect sizes are comparable to or larger than those accepted for many conditions where coverage is rarely debated.

Prior Authorization Requirements for Sildenafil on Horizon BCBS NJ Plans

Prior authorization (PA) is the most common coverage barrier members encounter. On plans that cover sildenafil, Horizon BCBS NJ typically requires PA before the first fill or after exceeding a set quantity limit.

Standard PA Criteria

Most PA criteria for sildenafil require:

1. A confirmed diagnosis of erectile dysfunction (ICD-10 code N52.x) documented in the medical record.
2. Confirmation that the prescribing provider is a licensed physician, nurse practitioner, or physician assistant with prescribing authority in New Jersey.
3. Documentation that nitrates or nitric oxide donors are NOT concurrently prescribed (an absolute contraindication per FDA label guidance).
4. Absence of other clinical contraindications listed in the FDA-approved prescribing information.
5. Quantity limits: most plans approve 6 tablets per 30-day supply, though some plans allow up to 8.

How Long PA Approval Takes

New Jersey state law (N.J.A.C. 11:24A-3.9) requires urgent PA decisions within 72 hours and routine PA decisions within 15 calendar days. Horizon BCBS NJ's internal timelines are generally consistent with this mandate. Your prescribing clinician submits the PA request; you do not need to file it yourself.

What Happens If PA Is Denied

A PA denial is not the end of the road. New Jersey's Consumer Protection rules, consistent with ACA Section 2719 internal appeal requirements, give you the right to:

• An internal appeal reviewed by a different clinical reviewer within Horizon BCBS NJ.
• An expedited appeal (within 72 hours) if your condition is urgent.
• An external independent medical review through the New Jersey Department of Banking and Insurance if the internal appeal fails.

Step-by-Step: How to Get Sildenafil Covered by Horizon BCBS NJ

Getting coverage approved follows a predictable sequence. Working systematically through each step reduces the chance of an avoidable denial.

Step 1. Verify Your Plan's Formulary

Log in to your Horizon BCBS NJ member portal and check the drug formulary. Search for both "sildenafil" and "Viagra." Note the tier, quantity limits, and whether PA is required. The Horizon BCBS NJ formulary search is updated periodically, so check it at the time of prescribing, not just at enrollment.

Step 2. Obtain a Formal ED Diagnosis

Your prescribing clinician must document the ED diagnosis in your chart using the appropriate ICD-10 code (N52.0 through N52.9). Organic causes, such as diabetes (E11.649), post-prostatectomy state (Z87.438), or atherosclerotic disease (I70.x), should also be coded because they strengthen medical necessity. CDC ICD-10 coding guidelines provide the authoritative coding reference.

Step 3. Submit the Prior Authorization

Your prescribing clinician submits the PA to Horizon BCBS NJ with the diagnosis codes, relevant comorbidities, and any supporting clinical notes. Include lab results (e.g., testosterone level, HbA1c) if they document an underlying medical cause of ED, because low testosterone is linked to ED per NIH data.

Step 4. Appeal If Denied

If the PA is denied, request the denial letter in writing. The letter must state the clinical reason and the specific criteria not met. Your clinician can then submit a letter of medical necessity addressing each denial criterion point by point. Studies published via PubMed-indexed research on appeal success rates suggest that physician-supported appeals overturn initial denials at rates between 39% and 59% depending on the condition and insurer.

Step 5. Request External Review If Needed

If the internal appeal fails, file for an external independent review through the New Jersey Department of Banking and Insurance. The external reviewer is a board-certified clinician independent of Horizon BCBS NJ. External review decisions are binding on the insurer under New Jersey law.

Cost Comparison: Covered vs. Out-of-Pocket Sildenafil

Understanding the actual dollar difference helps members decide whether to pursue coverage or pay cash.

With Insurance Coverage

On a Tier 1 or Tier 2 plan, a 30-day supply of generic sildenafil (6 tablets of 100 mg) might cost $10 to $30 copay. On a Tier 3 plan, the same supply could cost $40 to $80. FDA-approved generic sildenafil is manufactured by multiple companies including Teva, Mylan, and Greenstone, creating price competition.

Without Insurance Coverage

GoodRx and major pharmacy discount programs offer generic sildenafil 100 mg (6 tablets) for approximately $10 to $25 at many New Jersey pharmacies, without insurance. Brand Viagra 100 mg (6 tablets) can cost $400 or more without coverage. This cost gap is why most clinicians prescribe generic sildenafil first, even when brand coverage exists.

When Cash Pay Makes More Sense

If your Horizon BCBS NJ plan places sildenafil on a high tier with a $60 copay but GoodRx offers the same drug for $15, paying cash is cheaper. Using a discount card instead of insurance does not count toward your deductible, so the math depends on how far you are into your annual deductible.

Alternative ED Medications That May Be on Lower Tiers

If sildenafil is not covered or is cost-prohibitive on your plan, other PDE5 inhibitors may be available at lower tiers.

Tadalafil (Generic Cialis)

Tadalafil's U.S. Patent expired in 2018, and generic versions are now widely available. FDA approval records for generic tadalafil confirm multiple generic manufacturers. Some Horizon BCBS NJ plans tier generic tadalafil more favorably than generic sildenafil, particularly for daily dosing (2.5 mg or 5 mg), which may also carry a benign prostatic hyperplasia (BPH) indication that strengthens coverage arguments. A 2017 Cochrane review (N=7,990) confirmed that tadalafil 5 mg daily significantly improved IIEF scores versus placebo (mean difference 5.0, 95% CI 3.9-6.1, P<0.001) [3].

Vardenafil (Generic Levitra)

Generic vardenafil became available in the U.S. After 2018. PubMed-indexed RCT data for vardenafil show significant improvement in IIEF scores at 10 mg and 20 mg versus placebo (P<0.001, N=805). Its formulary placement varies considerably across Horizon BCBS NJ plan types.

Avanafil (Stendra)

Avanafil (brand name Stendra) remains under patent and is typically placed on a high non-preferred tier or excluded entirely. The FDA prescribing information for avanafil notes a faster onset of action (15-30 minutes) than sildenafil, which some patients prefer, but the cost differential is substantial.

The HealthRX ED Coverage Decision Framework below guides patients through the coverage pathway systematically. This framework was developed by the HealthRX clinical team based on published payer criteria, NJ insurance regulations, and FDA prescribing requirements:

HealthRX ED Coverage Decision Framework (Horizon BCBS NJ)

1. Check formulary online first (takes 5 minutes, saves multiple calls).
2. Confirm ICD-10 diagnosis code is in your chart before the prescription is sent.
3. Request PA at the same time as the prescription, not after a denial.
4. If denied, get the written denial reason before calling the insurer.
5. Compare cash-pay price via GoodRx before deciding whether to appeal.
6. File internal appeal within 30 days of denial.
7. If internal appeal fails, file external review with NJDOBI within 60 days of internal denial.

What New Jersey State Law Says About ED Drug Coverage

New Jersey has not enacted a specific mandate requiring commercial insurers to cover ED medications, unlike some states that mandate coverage of fertility treatments. However, several state and federal protections apply.

ACA Non-Discrimination and Essential Health Benefits

The ACA prohibits discriminatory benefit design that singles out specific conditions without clinical justification. HHS guidance on ACA Section 1557 non-discrimination is relevant when an ED exclusion appears to target a condition disproportionately affecting one sex. Legal challenges to blanket ED exclusions in employer plans have had mixed outcomes.

New Jersey State External Review Law

New Jersey mandates external independent review for denied claims involving medical necessity, per N.J.S.A. 26:2S-11. The external reviewer must be a board-certified clinician in a relevant specialty. The New Jersey Department of Banking and Insurance administers this process. External review decisions are issued within 45 days for standard reviews and 72 hours for expedited reviews.

Employer Self-Insured Plans and ERISA Preemption

If your employer self-insures (common in large New Jersey companies), your plan is governed by ERISA, not state insurance law. ERISA preempts most state insurance mandates. The Department of Labor's ERISA resources explain that self-insured plans still must follow ACA requirements but are exempt from many state-specific insurance mandates. Ask your HR department whether your plan is fully insured (subject to NJ state law) or self-insured (governed by ERISA).

Telehealth and Online Prescribing for Sildenafil in New Jersey

Since 2020, telehealth has become a primary access point for ED medications. New Jersey's telehealth prescribing law (N.J.S.A. 45:1-62) permits licensed clinicians to prescribe sildenafil via telehealth after an appropriate evaluation. FDA guidance on prescribing controlled and non-controlled substances via telehealth applies. Sildenafil is not a controlled substance, making telehealth prescribing relatively straightforward.

Insurance coverage for telehealth-prescribed sildenafil follows the same formulary rules as in-person prescriptions. Research published in JAMA Internal Medicine found that telehealth expansion significantly increased access to ED care, particularly for men in rural or underserved areas. Coverage parity laws in New Jersey (N.J.S.A. 26:2S-29.2) require insurers, including Horizon BCBS NJ, to reimburse telehealth services at parity with in-person visits for the consultation itself; the drug benefit rules remain the same.

How Testosterone Deficiency Interacts With Sildenafil Coverage

Low testosterone (hypogonadism) is a recognized organic cause of ED and may coexist with it in 10% to 40% of men with ED, per NIH data on hypogonadism and ED. Documenting a low serum testosterone level alongside the ED diagnosis strengthens the medical necessity argument for sildenafil coverage because it establishes an organic, treatable cause.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends testosterone therapy as first-line when hypogonadism is confirmed, but notes that PDE5 inhibitors may be added for men whose ED does not fully resolve with testosterone replacement alone. Documenting this clinical reasoning in the PA submission strengthens the case for covering both medications.

A PubMed-indexed meta-analysis of testosterone and ED treatment (N=1,761) confirmed that combined testosterone plus PDE5 inhibitor therapy produced greater IIEF improvement than either treatment alone (P<0.001), supporting the dual-agent approach when hypogonadism is present.

Documenting Medical Necessity: What Your Doctor Should Write

The letter of medical necessity is the single most influential document in a PA or appeal. Vague language leads to denials. Specific, evidence-based language leads to approvals.

Elements of an Effective Medical Necessity Letter

A strong letter includes:

• Patient's full name, date of birth, and Horizon BCBS NJ member ID.
• Specific ICD-10 code (e.g., N52.01 for erectile dysfunction due to arterial insufficiency).
• Duration of symptoms (e.g., "24 months of progressive erectile dysfunction").
• Relevant comorbidities with their own ICD-10 codes (e.g., E11.65 for type 2 diabetes with hyperglycemia).
• Lab values supporting organic etiology (e.g., "Total testosterone 187 ng/dL, below the Endocrine Society's lower normal limit of 264 ng/dL").
• Specific clinical evidence cited (e.g., Goldstein et al. NEJM trial [1], Cochrane PDE5 inhibitor review [2]).
• Statement that nitrates are not prescribed (required by FDA label).
• Requested dose, quantity, and duration.

Quote From Published Guideline Authority

The American Urological Association's erectile dysfunction guideline states: "Phosphodiesterase type 5 inhibitors are recommended as first-line oral therapy for erectile dysfunction." Including this direct guideline citation in a PA letter or appeal gives the clinical reviewer a named authoritative source supporting the request.

Special Populations and Coverage Considerations

Men After Prostate Cancer Treatment

Radical prostatectomy produces ED in the majority of patients, with rates depending on nerve-sparing technique and surgeon volume. PubMed-indexed data on post-prostatectomy ED indicate that early penile rehabilitation with PDE5 inhibitors may improve long-term recovery. ICD-10 code N52.01 (vasculogenic ED) or N52.34 (ED following radical prostatectomy) clearly establishes medical necessity in this population. Horizon BCBS NJ coverage denials in post-prostatectomy patients are among the most commonly overturned on appeal.

Men With Diabetes

Diabetic vascular disease and autonomic neuropathy both contribute to ED. Diabetes Care guidelines from the American Diabetes Association explicitly include ED assessment as part of diabetes management. This ADA guidance can be cited in PA submissions to demonstrate that sildenafil is part of standard diabetes care, not an elective treatment. The ADA guideline notes that "erectile dysfunction occurs in approximately 35-75% of men with diabetes."

Men With Cardiovascular Disease

The Princeton Consensus (III) recommendations, published in Mayo Clinic Proceedings and indexed on PubMed, stratify cardiovascular risk before PDE5 inhibitor use and recommend sildenafil for low-to-intermediate-risk patients. This risk stratification framework is often cited by insurers in their PA criteria; having it documented in the patient's chart supports the appropriateness of the prescription.